Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Faricimab Clear all
Completed Phase 2 Interventional Results available

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

NCT04597918
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Naples, Florida • Chicago, Illinois • Oak Forest, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

NCT06850922
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RO7446603, Aflibercept, Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
70
States / cities
Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Recruiting Phase 3 Interventional

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
34
States / cities
Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

NCT03622593
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
50
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 18, 2026, 7:41 AM EDT
Recruiting Phase 4 Interventional

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

NCT07695298
View directory record Official record
Conditions
Presumed Ocular Histoplasmosis
Interventions
Faricimab Injection [Vabysmo]
Drug
Lead sponsor
Cincinnati Eye Institute, Southwest Ohio
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Cincinnati, Ohio • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Recruiting Phase 3 Interventional

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

NCT05844982
View directory record Official record
Conditions
Radiation Retinopathy, Visual Impairment
Interventions
Faricimab, fluocinolone acetonide
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Enrolling by invitation Phase 4 Interventional

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

NCT06191094
View directory record Official record
Conditions
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions
Faricimab Injection, sham treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

NCT03622580
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 18, 2026, 7:41 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
Faricimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Santa Ana, California • Orlando, Florida • Winter Haven, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

NCT05224102
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Campbell, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT02484690
View directory record Official record
Conditions
Choroidal Neovascularization
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

NCT03038880
View directory record Official record
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 7:41 AM EDT
Active, not recruiting No phase listed Observational

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT04777201
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Faricimab, Sham Procedure, Anti-VEGF Therapy
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

NCT03823300
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

NCT04740931
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 18, 2026, 7:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

NCT07425522
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RO7823653, Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Peoria, Arizona • Beverly Hills, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

NCT03823287
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 18, 2026, 7:41 AM EDT
Active, not recruiting Phase 3 Interventional

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

NCT05904028
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
50 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
62
States / cities
Glendale, California • Loma Linda, California • Oakland, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Faricimab
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

NCT07484074
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Interventions
Faricimab, OLN324
Drug
Lead sponsor
Ollin Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Active, not recruiting Phase 4 Interventional

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

NCT05610319
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 18, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

NCT04432831
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
119
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 18, 2026, 7:41 AM EDT